Immunocore Holdings (Immunocore Holdings) Gross-Profit-to-Asset % : 35.38% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Immunocore Holdings Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Immunocore Holdings's annualized Gross Profit for the quarter that ended in Mar. 2024 was $357.1 Mil. Immunocore Holdings's average Total Assets over the quarter that ended in Mar. 2024 was $1,009.4 Mil. Therefore, Immunocore Holdings's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 35.38%.

Immunocore Holdings Gross-Profit-to-Asset % Historical Data

The historical data trend for Immunocore Holdings's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunocore Holdings Gross-Profit-to-Asset % Chart

Immunocore Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

13.70

15.92

14.56

40.47

45.00

Immunocore Holdings Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															45.41	43.90	44.90	80.61	35.38

Competitive Comparison of Immunocore Holdings's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Immunocore Holdings's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunocore Holdings's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunocore Holdings's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Immunocore Holdings's Gross-Profit-to-Asset % falls into.

Immunocore Holdings Gross-Profit-to-Asset % Calculation

Immunocore Holdings's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	314.419	/	( (641.61	+	755.697)	/ 2 )
	=	314.419	/	698.6535
	=	45.00 %

Immunocore Holdings's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	357.084	/	( (755.697	+	1263.008)	/ 2 )
	=	357.084	/	1009.3525
	=	35.38 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Immunocore Holdings Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Immunocore Holdings's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunocore Holdings (Immunocore Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunocore Holdings PLC (NAS:IMCR) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

6YG:Germany 6YG:Germany

Address

92 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY

Website

https://www.immunocore.com

Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.